CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis
NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to CRNX. CRNX was compared to 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CRNX has reported negative net income.
CRNX had a negative operating cash flow in the past year.
CRNX had negative earnings in each of the past 5 years.
CRNX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CRNX's Return On Assets of -24.11% is fine compared to the rest of the industry. CRNX outperforms 74.64% of its industry peers.
CRNX has a Return On Equity of -26.18%. This is amongst the best in the industry. CRNX outperforms 80.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.11% | ||
| ROE | -26.18% | ||
| ROIC | N/A |
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRNX has been increased compared to 1 year ago.
Compared to 5 years ago, CRNX has more shares outstanding
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 15.30 indicates that CRNX is not in any danger for bankruptcy at the moment.
CRNX has a Altman-Z score of 15.30. This is amongst the best in the industry. CRNX outperforms 91.19% of its industry peers.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 15.3 |
ROIC/WACCN/A
WACC9.77%
2.3 Liquidity
CRNX has a Current Ratio of 22.53. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX has a better Current ratio (22.53) than 95.32% of its industry peers.
CRNX has a Quick Ratio of 22.53. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRNX (22.53) is better than 95.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.53 | ||
| Quick Ratio | 22.53 |
3. Growth
3.1 Past
The earnings per share for CRNX have decreased by -1.06% in the last year.
Looking at the last year, CRNX shows a very negative growth in Revenue. The Revenue has decreased by -61.62% in the last year.
Measured over the past years, CRNX shows a decrease in Revenue. The Revenue has been decreasing by -2.68% on average per year.
EPS 1Y (TTM)-1.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
Revenue 1Y (TTM)-61.62%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%-43.59%
3.2 Future
CRNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.10% yearly.
CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 271.95% yearly.
EPS Next Y-23.48%
EPS Next 2Y-12.81%
EPS Next 3Y3.87%
EPS Next 5Y25.1%
Revenue Next Year210.48%
Revenue Next 2Y420.03%
Revenue Next 3Y398.76%
Revenue Next 5Y271.95%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.81%
EPS Next 3Y3.87%
5. Dividend
5.1 Amount
CRNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CRNX (7/22/2025, 2:25:36 PM)
30.79
-0.16 (-0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners110.82%
Inst Owner Change-0.01%
Ins Owners1.72%
Ins Owner Change21.82%
Market Cap2.88B
Analysts85.22
Price Target72.96 (136.96%)
Short Float %11.92%
Short Ratio13.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.7%
Min EPS beat(2)-8.34%
Max EPS beat(2)2.94%
EPS beat(4)1
Avg EPS beat(4)-4.01%
Min EPS beat(4)-8.34%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.72%
EPS beat(12)2
Avg EPS beat(12)-5.54%
EPS beat(16)3
Avg EPS beat(16)-6.6%
Revenue beat(2)1
Avg Revenue beat(2)94.65%
Min Revenue beat(2)-100%
Max Revenue beat(2)289.31%
Revenue beat(4)1
Avg Revenue beat(4)16.5%
Min Revenue beat(4)-100%
Max Revenue beat(4)289.31%
Revenue beat(8)4
Avg Revenue beat(8)44.77%
Revenue beat(12)7
Avg Revenue beat(12)111.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.43%
PT rev (3m)-5.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.67%
Revenue NQ rev (1m)-3.73%
Revenue NQ rev (3m)42.08%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)10%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3795.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.3 | ||
| P/tB | 2.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.82
EYN/A
EPS(NY)-4.72
Fwd EYN/A
FCF(TTM)-2.83
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.01
BVpS13.39
TBVpS13.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.11% | ||
| ROE | -26.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 115.92% | ||
| Cap/Sales | 493.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.53 | ||
| Quick Ratio | 22.53 | ||
| Altman-Z | 15.3 |
F-Score3
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
EPS Next Y-23.48%
EPS Next 2Y-12.81%
EPS Next 3Y3.87%
EPS Next 5Y25.1%
Revenue 1Y (TTM)-61.62%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%-43.59%
Revenue Next Year210.48%
Revenue Next 2Y420.03%
Revenue Next 3Y398.76%
Revenue Next 5Y271.95%
EBIT growth 1Y-51.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.02%
EBIT Next 3Y0.03%
EBIT Next 5YN/A
FCF growth 1Y-84.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.7%
OCF growth 3YN/A
OCF growth 5YN/A